Last updated: 20 June 2019 at 12:29am EST

James Altland Net Worth




The estimated Net Worth of James Altland is at least $10 millier dollars as of 30 July 2013. James Altland owns over 5,000 units of Onconova Therapeutics Inc stock worth over $10,000 and over the last 11 years James sold ONTX stock worth over $0.

James Altland ONTX stock SEC Form 4 insiders trading

James has made over 2 trades of the Onconova Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently James exercised 5,000 units of ONTX stock worth $30,000 on 30 July 2013.

The largest trade James's ever made was exercising 5,000 units of Onconova Therapeutics Inc stock on 30 July 2013 worth over $30,000. On average, James trades about 2,500 units every 0 days since 2013. As of 30 July 2013 James still owns at least 10,000 units of Onconova Therapeutics Inc stock.

You can see the complete history of James Altland stock trades at the bottom of the page.



What's James Altland's mailing address?

James's mailing address filed with the SEC is C/O ONCONOVA THERAPEUTICS, INC., 375 PHEASANT RUN, NEWTOWN, PA, 18940.

Insiders trading at Onconova Therapeutics Inc

Over the last 12 years, insiders at Onconova Therapeutics Inc have traded over $1,631,795 worth of Onconova Therapeutics Inc stock and bought 27,892,613 units worth $51,994,589 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Management, Llc 683 et Capital Partners L P Tyndall. On average, Onconova Therapeutics Inc executives and independent directors trade stock every 40 days with the average trade being worth of $294,478. The most recent stock trade was executed by Mark Patrick Guerin on 13 March 2024, trading 8,666 units of ONTX stock currently worth $8,666.



What does Onconova Therapeutics Inc do?

onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.



Complete history of James Altland stock trades at Onconova Therapeutics Inc

Initié
Trans.
Transaction
Prix ​​total
James Altland
Vice-président senior, Finance et Corp. Develop.
Exercice d'option $30,000
30 Jul 2013
James Altland
Vice-président senior, Finance et Corp. Develop.
Exercice d'option $30,000
30 Jul 2013


Onconova Therapeutics Inc executives and stock owners

Onconova Therapeutics Inc executives and other stock owners filed with the SEC include: